Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from BeiGene Ltd ( (HK:6160) ) is now available.
BeOne Medicines Ltd. has established a Scientific Advisory Committee to enhance its board’s oversight of research and development activities, providing strategic scientific guidance. This move aims to bolster the company’s R&D capabilities, ensuring alignment with its strategic goals, and potentially strengthening its position within the pharmaceutical industry.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,619,453
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$235.8B
Learn more about 6160 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue